374Water experienced a dramatic deterioration in financial performance with substantially reduced revenue, meaningfully expanded losses, and a significant decline in cash position and stockholders' equity.
The company's financial condition has weakened considerably, with revenue declining substantially while operating losses expanded meaningfully year-over-year. The sharp reduction in current assets from $14.9M to $5.9M, combined with declining stockholders' equity, raises concerns about the company's liquidity position and ability to fund ongoing operations without additional capital raises.
374Water's financial performance deteriorated across all key metrics, with revenue declining substantially while both net losses and operating losses expanded meaningfully. The balance sheet shows significant stress with current assets falling 60.7% to $5.9M and stockholders' equity declining 56.5% to $6.7M, while liabilities increased modestly. Operating cash flow remained deeply negative at -$14.3M, worsening from the prior year's -$10.6M, painting a concerning picture of a company burning through cash while generating minimal revenue in its cleantech operations.
Net income declined 68.7% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Current assets declined 60.7% — monitor working capital adequacy and short-term liquidity.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Revenue declined 51.7% — significant demand weakness or market share loss warrants investigation.
Total assets contracted 40.5% — asset sales, write-downs, or balance sheet optimization underway.
Operating cash flow fell 35.3% — earnings quality concerns; investigate working capital changes and non-cash items.
Current liabilities surged 33.8% — significant near-term obligations; verify ability to meet short-term debt.
Liabilities increased 26.2% — monitor debt-to-equity ratio and interest coverage.
R&D investment increased 17.8% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →